Astec LifeSciences Reports Strong FY21 Results, Recommends 15% Final Dividend

Astec LifeSciences Limited , a prominent player in the agrochemicals segment, has announced its audited financial results for the fiscal year 2020-21, showcasing robust growth and improved profitability.

Financial Highlights

The company reported a significant increase in standalone profit for the year ended March 31, 2021. Here are the key financial highlights:

Metric	FY 2020-21	FY 2019-20	Change
Standalone Profit	₹6,469.25 lakh	₹4,747.19 lakh	36.28%
Revenue from Operations	₹55,487.21 lakh	₹52,222.09 lakh	6.25%
Basic Earnings Per Share	₹33.05	₹24.27	36.18%

The company's performance demonstrates strong growth, with a 36.28% increase in standalone profit and a 6.25% rise in revenue from operations compared to the previous fiscal year.

Dividend Announcement

In light of the company's strong financial performance, the Board of Directors has recommended a final dividend of 15% (₹1.50 per share of face value ₹10). This dividend is subject to shareholder approval at the upcoming Annual General Meeting.

Annual General Meeting

Astec LifeSciences has scheduled its 27th Annual General Meeting for July 28, 2021, where shareholders will have the opportunity to review the company's performance and vote on key matters, including the proposed dividend.

Financial Position

As of the reported period, Astec LifeSciences maintains a healthy financial position:

Debt-Equity Ratio: 0.61
Net Worth: ₹308.70 crore

These figures indicate a balanced capital structure and a solid financial foundation for the company.

Industry Context

Astec LifeSciences operates in the agrochemicals segment, a sector crucial for agricultural productivity and food security. The company's growth in revenue and profitability suggests a positive market environment and effective business strategies in this important industry.

The strong financial results and the decision to recommend a dividend reflect the company's commitment to delivering value to its shareholders while maintaining a robust financial position for future growth and investments in the agrochemicals sector.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.63%	-2.24%	-15.83%	-2.18%	-34.43%	-38.02%

Godrej Agrovet Limited has significantly increased its shareholding in Astec LifeSciences Limited, a move that strengthens its position as a promoter of the company. The acquisition, completed on July 29, 2025, saw Godrej Agrovet's stake rise from 63.36% to 67.03% through a combination of open market purchases and participation in a rights issue.

Transaction Details

Godrej Agrovet acquired an additional 25,31,229 shares in Astec LifeSciences, bringing its total holding to 1,49,35,245 shares. This strategic move was executed through two channels:

Open market purchases
Participation in a rights issue

The transaction resulted in a notable increase in Astec LifeSciences' equity share capital, which expanded from Rs. 19.61 crore to Rs. 22.28 crore.

Shareholding Structure

The following table illustrates the change in Godrej Agrovet's shareholding in Astec LifeSciences:

Particulars	Before Acquisition	After Acquisition
Number of Shares	1,24,04,016	1,49,35,245
Shareholding Percentage	63.36%	67.03%
Total Share Capital (in Rs.)	19,61,17,100	22,28,16,610

Regulatory Compliance

In compliance with regulatory requirements, Godrej Agrovet filed a disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This filing, dated July 31, 2025, provides detailed information about the transaction to both the BSE Limited and the National Stock Exchange of India Limited, where Astec LifeSciences is listed.

The acquisition underscores Godrej Agrovet's commitment to Astec LifeSciences and may signal confidence in the company's future prospects. As a promoter entity, this increased stake could potentially lead to greater strategic alignment between the two companies in the agrochemical and life sciences sectors.